IN8bio Inc (INAB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.20+3.45%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INAB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
INAB — divestiture
Dated 2026-06-01
Entry into a Material Definitive Agreement. On June 1, 2026, IN8bio, Inc. (the “ Company ”) entered into a Capital on Demand TM Sales Agreement (the “ Sales Agreement ”) with JonesTrading Institutional Services LLC (the “ Agent ”) with respect to an at the market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares (the “ Placement Shares ”) of its common stock, par value $0.0001 per share (the “ Common Stock ”), through or to the Agent…
Why it matters: Initial data will show how well INB-619 works in animal models. This is key for future studies.
Supportive ifInitial in vivo data for INB-619 is reported in the second half of 2026.
Worry ifNo data is reported by the end of 2026.
Why it matters: Guidance could help explain the regulatory path for DeltEx DRI and its timeline.
Supportive ifThe FDA shares ideas on how to regulate the glioblastoma program.
Worry ifThere is no news or guidance from the FDA on the glioblastoma program.
Why it matters: Guidance from the FDA will clarify the path forward for the glioblastoma program. Positive feedback could speed up development.
Supportive ifFDA gives clear guidance on rules for the DeltEx DRI program.
Worry ifFDA feedback shows big challenges or delays for the DeltEx DRI program.
Why it matters: Better operating losses show that management cares about cash flow. This can help investors feel good.
Supportive ifQ2 operating losses drop from negative $5.1 million in Q1.
Worry ifQ2 operating losses worsen or remain flat compared to Q1.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$250 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $796 loss on $10,000 · 8.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,293 loss on $10,000 · 62.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New survival data will show how well the DeltEx DRI treatment works for glioblastoma.
Supportive ifNew median overall survival data is over 19.5 months at ASCO 2026.
Worry ifOverall survival data does not get better or gets worse at ASCO 2026.
Why it matters: Leadership changes can affect strategy and operations. Investors need to see the new path.
Watch forA new executive has been announced. They have the right experience and a clear plan.
Also watch forThere is ongoing uncertainty. There is also bad feedback about the leadership change.
Why it matters: A drop in cash could mean financial trouble. This may affect projects and operations.
Worry ifThe company has more than $18 million in cash. This helps keep operations running.
Less concerning ifCash position is below $18 million, which may signal financial problems.
Why it matters: New survival data will show how well DeltEx DRI works for glioblastoma. Good results may bring more interest.
Supportive ifPatients with glioblastoma live more than 19.5 months when treated with DeltEx DRI.
Worry ifOverall survival does not get better or drops compared to earlier data.
Why it matters: New partnerships can provide funding and resources. This is important for growth.
Supportive ifA new partnership is announced with funding or resource sharing.
Worry ifNo new partnerships announced in the next quarter.
Why it matters: FDA guidance will clarify the next steps for the glioblastoma treatment program. This is crucial for future development.
Supportive ifFDA will share guidance on glioblastoma program pathways in 2H 2026.
Worry ifNo guidance is received or reported by the end of 2026.
Why it matters: A drop below this level could signal financial strain and impact ongoing projects.
Worry ifCash position remains above $15 million at the end of 2026.
Less concerning ifCash position drops below $15 million by the end of 2026.
Why it matters: The R&D Day will provide insights into IN8bio's pipeline and strategic direction. Key updates could influence market perception.
Watch forThere is good news about partnerships or clinical results during R&D Day.
Also watch forThere are no big updates or negative comments about the pipeline.